

# A study of JNJ-77242113 for the treatment of participants with plaque psoriasis involving special areas (scalp, genital, and/or palms of hands and the soles of the feet)

<b>Submission date</b> 17/08/2023	<b>Recruitment status</b> No longer recruiting	<input type="checkbox"/> Prospectively registered
<b>Registration date</b> 23/10/2023	<b>Overall study status</b> Ongoing	<input type="checkbox"/> Protocol
<b>Last Edited</b> 08/04/2024	<b>Condition category</b> Skin and Connective Tissue Diseases	<input type="checkbox"/> Statistical analysis plan
		<input type="checkbox"/> Results
		<input type="checkbox"/> Individual participant data
		<input type="checkbox"/> Record updated in last year

## Plain English Summary

Background and study aims

Plaque psoriasis is a skin disease that causes red, scaly, and sometimes painful and itchy patches on the skin.

Drugs that prevent interleukin IL-23\* from binding to its receptor\*\* may be an effective way to disease control. JNJ-77242113 is designed to target IL-23 receptor and block IL-23 from binding to it.

(\*A specific type of protein involved in inflammation.)

(\*\*A protein that binds to specific molecule.)

The purpose of this study is to see how effective JNJ-77242113 is in participants with plaque psoriasis involving special areas (scalp, genital, and/or palms of the hands and the soles of the feet).

Participants will receive JNJ-77242113 or placebo in a 2:1 ratio which means in every 2 participants who receive JNJ-77242113, 1 will receive placebo. JNJ-77242113 will be administered in all treatment groups (JNJ-77242113, placebo). This is a double-blind study, which means participant, caregiver, and study doctor will not know whether the participants are receiving JNJ-77242113 or placebo.

Who can participate?

Participants aged 18 years or older (in the UK) and aged 12 years or older (countries other than UK) with plaque psoriasis involving special areas (scalp, genital, and/or palms of the hands and the soles of the feet).

What does the study involve?

The study will be conducted in 3 periods:

1. Screening period (5 weeks)

2. Double-blind (156 weeks) treatment period: Participants will be randomly (like flip of a coin) divided to 2 groups:

Group 1: JNJ-77242113 orally from Week 0 through Week 156.

Group 2: Matching placebo of JNJ-77242113 orally from Week 0 through Week 16 and thereafter, JNJ-77242113 orally through Week 156.

Participants will undergo study assessments and tests, such as questionnaires, blood tests, vital signs, and physical exams. Blood samples will be taken at multiple timepoints to understand how the body responds to the study drug.

Follow-up period (4 weeks): Participants will be monitored for their health after the last dose of study drug until the study ends.

All side effects will be recorded until the study ends. The total study duration is approximately 3 years and 2 months.

What are the possible benefits and risks of participating?

There is no established benefit to participants of this study. Based on scientific theory, taking JNJ-77242113 may reduce plaque psoriasis (red, scaly, itchy patches on the skin). However, this cannot be guaranteed because JNJ-77242113 is still under investigation as a treatment and it is not known whether JNJ-77242113 will work.

If participants are put into the placebo treatment group, they will not receive JNJ-77242113 up to Week 16. Participants will start receiving JNJ-77242113 from Week 16 through Week 156 during this study.

Participants may experience some benefit from participation in the study that is not due to receiving JNJ-77242113, but due to regular visits and assessments monitoring overall health.

Participation may help other people with plaque psoriasis in the future.

Participants may have side effects from the drugs or procedures used in this study that may be mild to severe and even life-threatening, and they can vary from person to person. Potential risks include hypersensitivity reactions, anti-drug antibody production, and infection. Skin biopsy (optional procedure) may cause mild bleeding, pain, discomfort, scarring, discoloration, and infection. The participant information sheet and informed consent form, which will be signed by every participant agreeing to participate in the study, includes a detailed section outlining the known risks of participating in the study.

Not all possible side effects related to JNJ-77242113 are known at this moment. During the study, the sponsor may learn new information about JNJ-77242113. The study doctor will tell participants as soon as possible about any new information that might make them change their mind about being in the study, such as new risks.

To minimize the risk associated with taking part in the study, participants are frequently reviewed for any side effects and other medical events. Participants are educated to report any such events to the study doctor who will provide appropriate medical care. Any serious side effects that are reported to the sponsor are thoroughly reviewed by a specialist drug safety team.

There are no costs to participants to be in the study. The sponsor will pay for the study drug and tests that are part of the study. The participant will receive reasonable reimbursement for study-related costs (e.g., travel/parking costs).

Where is the study run from?

Janssen-Cilag International NV is the sponsor for this study. The study will be run at multiple healthcare locations both within the UK and around the world.

When is the study starting and how long is it expected to run for?

August 2023 to June 2027

Who is funding the study?

Janssen Research & Development, LLC

Who is the main contact?

Sarah Currie, JanssenUKRegistryQueries@its.jnj.com

## Contact information

### Type(s)

Scientific

### Contact name

Dr Medical Information and Product Information Enquiry

### Contact details

50-100 Holmers Farm Way

High Wycombe

United Kingdom

HP12 4DP

+44 (0)800 731 8450 / 10494 567 444

medinfo@its.jnj.com

### Type(s)

Principal Investigator

### Contact name

Dr Michelle Oakford

### Contact details

Tremona Road

Southampton

United Kingdom

SO16 6YD

## Additional identifiers

### EudraCT/CTIS number

2023-505122-34

### IRAS number

1008238

### ClinicalTrials.gov number

NCT06095102

### Secondary identifying numbers

77242113PSO3003, IRAS 1008238, CPMS 57585

## Study information

Scientific Title

A Phase III multicenter, randomized double-blind, placebo-controlled study to evaluate the efficacy and safety of JNJ-77242113 for the treatment of participants with plaque psoriasis involving special areas

## **Acronym**

ICONIC-TOTAL

## **Study hypothesis**

Main objectives

1. To evaluate the effectiveness of JNJ-77242113 in participants with plaque psoriasis involving special areas.

Secondary objectives

1. To evaluate the effectiveness (in general psoriasis and special area psoriasis) of JNJ-77242113 in participants with plaque psoriasis involving special areas.

2. To evaluate how effective JNJ-77242113 is on patient-related outcomes (PROs) in participants with plaque psoriasis involving special areas.

3. To assess the safety, tolerability, and effect of JNJ-77242113 in participants with plaque psoriasis involving special areas.

4. To further evaluate the effect of JNJ-77242113 on PROs in participants with plaque psoriasis involving special areas.

## **Ethics approval required**

Ethics approval required

## **Ethics approval(s)**

Approved 20/10/2023, North West – Liverpool Central Research Ethics Committee (2 Redman Place, Stratford, London, E20 1JQ, United Kingdom; +44 (0)207 104 8118; liverpoolcentral.rec@hra.nhs.uk), ref: 23/NW/0268

## **Study design**

Randomized placebo-controlled double-blind trial

## **Primary study design**

Interventional

## **Secondary study design**

Randomised controlled trial

## **Study setting(s)**

Hospital

## **Study type(s)**

Treatment, Safety, Efficacy

## **Participant information sheet**

Not available in web format, please use the contact details to request a participant information sheet

## **Condition**

Plaque psoriasis

## Interventions

The total duration of this study is up to 165 weeks, which includes an up to 5-week screening period, a 156-week treatment period, and a 4-week safety follow-up period. At the beginning of the treatment period, participants will be randomly (like a flip of a coin) divided into one of two treatment groups:

Group 1: receive JNJ-77242113 orally from Week 0 through Week 156

Group 2: receive placebo from Week 0 through Week 16 and thereafter will receive JNJ-77242113 from Week 16 through Week 156.

## Intervention Type

Drug

## Pharmaceutical study type(s)

Pharmacokinetic, Pharmacodynamic, Pharmacogenomic

## Phase

Phase III

## Drug/device/biological/vaccine name(s)

JNJ-77242113

## Primary outcome measure

Percentage of participants achieving an Investigator's Global Assessment (IGA) Score of 0 or 1 and Greater Than or Equal to ( $\geq$ ) 2 Grade Improvement from Baseline at Week 16. The IGA documents the investigator's assessment of the participant's psoriasis at a given time point. Overall lesions are graded for induration, erythema, and scaling. The participant's psoriasis is assessed as cleared (0), minimal (1), mild (2), moderate (3), or severe (4).

## Secondary outcome measures

1. Percentage of participants achieving Scalp-specific Investigator Global Assessment (ss-IGA) Score of 0 or 1 at Week 16. The ss-IGA instrument is used to evaluate the disease severity of scalp psoriasis. The lesions are assessed in terms of the clinical signs of redness, thickness, and scaliness which are scored as: absence of disease (0), very mild disease (1), mild disease (2), moderate disease (3), and severe disease (4).
2. Percentage of participants achieving Psoriasis Scalp Severity Index (PSSI) 90 at Week 16. The PSSI is a scalp-specific modification of the PASI based on the extent of involvement and the severity of erythema, infiltration, and desquamation. Involvement and severity of psoriasis on the PSSI is scored by physicians on a scale from 0 to 72, where 0 = no psoriasis and higher scores indicate more severe disease.
3. Percentage of participants achieving a Static Physician's Global Assessment of Genitalia (sPGA-G) Score of 0 or 1 at Week 16. The sPGA-G is a 6-point scale to assess the severity of genital psoriasis at a given time point. The sPGA-G evaluates erythema, plaque elevation, and scale of genital psoriatic lesions. The severity of genital psoriasis is assessed as clear (0), minimal (1), mild (2), moderate (3), severe (4), and very severe (5).
4. Percentage of participants achieving a Physician's Global Assessment of Hands and Feet (hf-PGA) Score of 0 or 1 at Week 16. The hf-PGA assesses the severity of hand and foot psoriasis using a 5-point scale to score the plaques on the hands and feet as: clear (0), almost clear (1), mild (2), moderate (3), and severe (4).
5. Percentage of participants achieving Psoriasis Symptom and Sign Diary (PSSD) Symptoms Score of 0 at Week 16. The PSSD includes a patient-reported outcome (PRO) questionnaire

designed to measure the severity of psoriasis symptoms and signs over the previous 7 days for the assessment of treatment benefit. The PSSD is a self-administered PRO instrument that includes 11 items covering symptoms (itch, pain, stinging, burning, and skin tightness) and patient-observable signs (skin dryness, cracking, scaling, shedding or flaking, redness, and bleeding) using 0 to 10 numerical rating scales for severity. Two sub-scores will be derived each ranging from 0 to 100: the psoriasis symptom score and the psoriasis sign score. A higher score indicates more severe disease.

6. Percentage of participants achieving  $\geq 4$  point improvement from baseline in PSSD itch score at Week 16. The PSSD includes a PRO questionnaire designed to measure the severity of psoriasis symptoms and signs over the previous 7 days for the assessment of treatment benefit. The PSSD is a self-administered PRO instrument that includes 11 items covering symptoms (itch, pain, stinging, burning, and skin tightness) and patient-observable signs (skin dryness, cracking, scaling, shedding or flaking, redness, and bleeding) using 0 to 10 numerical rating scales for severity. Two sub-scores will be derived each ranging from 0 to 100: the psoriasis symptom score and the psoriasis sign score. A higher score indicates more severe disease.

7. Percentage of participants achieving Genital Psoriasis Sexual Frequency Questionnaire (GenPs-SFQ) Item 2 score of 0 or 1 at Week 16. The GenPs-SFQ is a 2-item participant-reported instrument used to assess the impact of genital psoriasis on the frequency of sexual activity in the last 7 days. Item 1 assesses the overall frequency of sexual activity in the last 7 days (none /zero, once, or 2 or more times), and item 2 assesses how frequently genital psoriasis symptoms have limited the frequency of sexual activity in the last 7 days (never [0], rarely [1], sometimes [2], often [3], or always [4]).

8. Percentage of participants achieving  $\geq 4$ -point improvement from baseline in Scalp Itch Numeric Rating Scale (NRS) Score at Week 16. The Scalp Itch NRS is a single-item instrument that evaluates the severity of scalp itch in adult and adolescent populations over the past 24 hours. The instrument uses an NRS score ranging from 0 (no scalp itch) to 10 (worst scalp itch imaginable).

9. Percentage of participants achieving  $\geq 4$ -point Improvement from Baseline in Genital Psoriasis Symptoms Scale (GPSS) Genital Itch NRS Score at Week 16. The GPSS is a participant-administered assessment of 8 symptoms: itch, pain, discomfort, stinging, burning, redness, scaling, and cracking. Each respondent is asked to answer the questions based on the psoriasis symptoms in his or her genital area. The overall severity for each individual genital psoriasis symptom is indicated by selecting the number from an NRS of 0 to 10 that best describes the worst level of each symptom in the genital area in the past 24 hours, ranging from 0 (no severity) to 10 (worst imaginable severity).

10. Number of participants with adverse events (AEs) up to week 165. An adverse event (AE) is any untoward medical event that occurs in a participant administered an investigational product, and it does not necessarily indicate only events with clear causal relationship with the relevant investigational product.

11. Number of participants with serious adverse events (SAEs) up to week 165. An SAE is any AE which results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, is a suspected transmission of any infectious agent via a medicinal product, or is medically important.

12. Percentage of participants achieving Psoriasis Area and Severity Index (PASI) 90 Response at Week 16. The PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas is assessed and scored separately for erythema, induration, and scaling, which are each rated on a scale of 0 to 4 and extent of involvement on a scale of 0 to 6. The PASI produces a numeric score that can range from 0 to 72. A higher score indicates more severe disease.

13. Percentage of participants achieving PASI 75 Response at Week 16. The PASI is a system

used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas is assessed and scored separately for erythema, induration, and scaling, which are each rated on a scale of 0 to 4 and extent of involvement on a scale of 0 to 6. The PASI produces a numeric score that can range from 0 to 72. A higher score indicates more severe disease.

14. Change from baseline in PASI Total Score at Week 16. The PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body is divided into 4 regions: head, trunk, upper, and lower extremities. Each of these areas is assessed separately for the percentage of the area involved, which translates to a numeric score that ranges from 0 (indicates no involvement) to 6 (90% to 100% involvement), and for erythema, induration, and scaling, which are each rated on a scale of 0 (none) to 4 (severe). The PASI produces a numeric score that can range from 0 to 72. A higher score indicates more severe disease.

15. Change from baseline in BSA at Week 16. BSA is a commonly used measure of extent of skin disease. It is defined as the percentage of surface area of the body involved with the condition being assessed (that is, plaque psoriasis).

16. Percent change from baseline in Modified Nail Psoriasis Areas and Severity Index (mNAPSI) Score at Week 16. The mNAPSI is an index used for assessing and grading the severity of nail psoriasis. Each of the participant's ten fingernails are evaluated on 7 features. The first three features are each scored from 0 to 3 in severity and are (1) onycholysis and oil-drop dyschromia, (2) pitting, and (3) nail plate crumbling. The next four features are each scored 0 –absent or 1 – present, and are (1) leukonychia, (2) splinter hemorrhages, (3) nail bed hyperkeratosis, and (4) red spots in the lunula. The score ranges from 0-13 per nail, and 0-130 for all fingernails.

17. Percentage of participants achieving Fingernail Physician's Global Assessment (f-PGA) Score of 0 or 1 at Week 16. The f-PGA is used to evaluate the current status of a participant's fingernail psoriasis on a scale of 0 to 4 similar (clear [0], minimal [1], mild [2], moderate [3], or severe [4]). A higher score indicated severe disease.

18. Percentage of participants achieving an IGA Score of 0 at Week 16. The IGA documents the investigator's assessment of the participant's psoriasis at a given time point. Overall lesions are graded for induration, erythema, and scaling. The participant's psoriasis is assessed as cleared (0), minimal (1), mild (2), moderate (3), or severe (4).

19. Percentage of participants achieving PSSD Symptom Score of 0 at Week 8. The PSSD includes a PRO questionnaire designed to measure the severity of psoriasis symptoms and signs over the previous 7 days for the assessment of treatment benefit. The PSSD is a self-administered PRO instrument that includes 11 items covering symptoms (itch, pain, stinging, burning, and skin tightness) and patient-observable signs (skin dryness, cracking, scaling, shedding or flaking, redness, and bleeding) using 0 to 10 numerical rating scales for severity. Two sub-scores will be derived each ranging from 0 to 100: the psoriasis symptom score and the psoriasis sign score. A higher score indicates more severe disease.

20. Change from baseline in PSSD Symptom Score at Week 16. The PSSD includes a PRO questionnaire designed to measure the severity of psoriasis symptoms and signs over the previous 7 days for the assessment of treatment benefit. The PSSD is a self-administered PRO instrument that includes 11 items covering symptoms (itch, pain, stinging, burning, and skin tightness) and patient-observable signs (skin dryness, cracking, scaling, shedding or flaking, redness, and bleeding) using 0 to 10 numerical rating scales for severity. Two sub-scores will be derived each ranging from 0 to 100: the psoriasis symptom score and the psoriasis sign score. A higher score indicates more severe disease.

21. Percentage of participants achieving  $\geq 4$ -point improvement from baseline in PSSD Itch Score at Week 4. The PSSD includes a PRO questionnaire designed to measure the severity of psoriasis symptoms and signs over the previous 7 days for the assessment of treatment benefit. The PSSD is a self-administered PRO instrument that includes 11 items covering symptoms (itch,

pain, stinging, burning, and skin tightness) and patient-observable signs (skin dryness, cracking, scaling, shedding or flaking, redness, and bleeding) using 0 to 10 numerical rating scales for severity. Two sub-scores will be derived each ranging from 0 to 100: the psoriasis symptom score and the psoriasis sign score. A higher score indicates more severe disease.

22. Change from baseline in PSSD sign score at Week 16. The PSSD includes a PRO questionnaire designed to measure the severity of psoriasis symptoms and signs over the previous 7 days for the assessment of treatment benefit. The PSSD is a self-administered PRO instrument that includes 11 items covering symptoms (itch, pain, stinging, burning, and skin tightness) and patient-observable signs (skin dryness, cracking, scaling, shedding or flaking, redness, and bleeding) using 0 to 10 numerical rating scales for severity. Two sub-scores will be derived each ranging from 0 to 100: the psoriasis symptom score and the psoriasis sign score. A higher score indicates more severe disease.

23. Percentage of participants achieving PSSD Sign Score of 0 at Week 16. The PSSD includes a PRO questionnaire designed to measure the severity of psoriasis symptoms and signs over the previous 7 days for the assessment of treatment benefit. The PSSD is a self-administered PRO instrument that includes 11 items covering symptoms (itch, pain, stinging, burning, and skin tightness) and patient-observable signs (skin dryness, cracking, scaling, shedding or flaking, redness, and bleeding) using 0 to 10 numerical rating scales for severity. Two sub-scores will be derived each ranging from 0 to 100: the psoriasis symptom score and the psoriasis sign score. A higher score indicates more severe disease.

24. Percentage of participants achieving a Dermatology Life Quality Index (DLQI) Score of 0 or 1 at Week 16. The DLQI is a dermatology-specific health-related quality of life (HRQoL) instrument designed to assess the impact of the disease on a participant's HRQoL. It is a 10-item questionnaire that assesses HRQoL over the past week and in addition to evaluating overall HRQoL, can be used to assess 6 different aspects that may affect quality of life: symptoms and feelings, daily activities, leisure, work or school performance, personal relationships, and treatment. The total score ranges from 0 to 30 with a higher score indicating greater impact on HRQoL.

25. Percentage of participants achieving Children's Dermatology Life Quality Index (CDLQI) score of 0 or 1 at Week 16. The CDLQI is a dermatology-specific quality of life (QoL) instrument designed to assess the impact of the disease on a child's QoL. The CDLQI, a 10-item questionnaire has 4-item response options and a recall period of 1 week. The CDLQI is calculated by summing the score of each question resulting in a maximum of 30 and a minimum of 0; the higher the score, the greater the impairment in QoL.

26. Change from baseline in Domain Scores of the Patient-reported Outcomes Measurement Information System-29 (PROMIS-29) Score at Week 16. The PROMIS-29 is a 29-item generic HRQoL instrument assessing 7 PROMIS domains (depression, anxiety, physical function, pain interference, fatigue, sleep disturbance, and ability to participate in social roles and activities) with 4 questions for each domain. These questions are ranked on a 5-point Likert scale. There is also a numerical rating scale that ranges from 0 (No pain) to 10 (Worst pain imaginable) for pain intensity. The raw domain scores are converted to standardized T-scores with a mean of 50 and a standard deviation of 10. Higher scores on anxiety, depression, fatigue, sleep disturbance, and pain interference indicate more severe symptoms. Higher scores on physical function and social participation indicate better health outcomes.

27. Change from baseline in Domain Scores of the Patient-reported Outcomes Measurement Information System-25 (PROMIS-25) Score at Week 16. The PROMIS-25 will be utilized in the adolescent population and is a 25-item generic HRQoL survey. Six PROMIS domains (physical function mobility, anxiety, depressive symptoms, fatigue, peer relationships, pain interference) are each assessed with 4 questions. There is also one 11-point rating scale for pain intensity. The instrument is designed for use in ages 8-17 years of age and can be self-administered.

28. Change from baseline in Palmoplantar Quality of Life Instrument (ppQLI) Score at Week 16. The ppQLI assesses the impact on patient quality of life due to palmoplantar psoriasis over the



past month in adult and adolescent populations. Fifteen items evaluate hand functionality, pain, and social impact due to psoriasis. Fourteen items evaluate foot functionality, pain, and physical limitations due to psoriasis. All items use verbal rating scales ranging from 1 to 5. The ppQLI yields a score for hands, ranging from 15 to 80, and a score for feet, ranging from 14 to 70.

29. Change from baseline in Genital Psoriasis Symptoms Scale (GPSS) Total Score at Week 16. The GPSS is a participant-administered assessment of 8 symptoms: itch, pain, discomfort, stinging, burning, redness, scaling, and cracking. Each respondent is asked to answer the questions based on the psoriasis symptoms in his or her genital area. The overall severity for each individual genital psoriasis symptom is indicated by selecting the number from an NRS of 0 to 10 that best describes the worst level of each symptom in the genital area in the past 24 hours, ranging from 0 (no severity) to 10 (worst imaginable severity).

**Overall study start date**

15/08/2023

**Overall study end date**

14/06/2027

## Eligibility

**Participant inclusion criteria**

1. Aged 18 years or older
2. Diagnosis of plaque psoriasis, with or without psoriatic arthritis (PsA), for at least 26 weeks prior to the first administration of study intervention
3. Candidate for phototherapy or systemic treatment for plaque psoriasis
4. Need to meet criteria:
  - 4.1. Total body surface area (BSA) greater than or equal to ( $\geq$ ) 1 percent (%) at screening and baseline,
  - 4.2. and investigator global assessment (IGA) (overall)  $\geq$  2 at screening and baseline
  - 4.3. and at least one of the following: scalp-specific investigator global assessment (ss-IGA) score  $\geq$  3 at screening and baseline, and/or
  - 4.4. static physician's global assessment of genitalia (sPGA-G)  $\geq$  3 at screening and baseline, and /or physician's global assessment of hands and feet (hf-PGA) score  $\geq$  3 at screening and baseline
5. Failed to respond to at least 1 topical therapy (example, corticosteroids, calcineurin inhibitors, and/or vitamin D analogs) used for treatment of psoriasis
6. Confirmation of plaque psoriasis in a non-special area (example, areas excluding scalp, genital, palmoplantar) at screening and baseline

**Participant type(s)**

Patient

**Age group**

Adult

**Lower age limit**

18 Years

**Sex**

Both

**Target number of participants**

300

**Participant exclusion criteria**

1. Nonplaque form of psoriasis (example, erythrodermic, guttate, or pustular)
2. Dermatoses other than plaque psoriasis (such as contact dermatitis) or palmoplantar pustulosis of the palmoplantar area (if hf-PGA  $\geq 3$  at baseline)
3. Current drug-induced psoriasis (example, a new onset of psoriasis or an exacerbation of psoriasis from beta blockers, calcium channel blockers, or lithium)
4. A current diagnosis or signs or symptoms of severe, progressive, or uncontrolled renal, liver, cardiac, vascular, pulmonary, gastrointestinal, endocrine, neurologic, haematologic, rheumatologic, psychiatric, or metabolic disturbances
5. Known allergies, hypersensitivity, or intolerance to JNJ-77242113 or its excipients

**Recruitment start date**

12/10/2023

**Recruitment end date**

01/04/2024

**Locations****Countries of recruitment**

Argentina

Canada

Germany

Hungary

Korea, South

Poland

Spain

Taiwan

Türkiye

United Kingdom

United States of America

**Study participating centre**

**Centro Privado de Medicina Familiar**

Jose Pedro Varela 3954

Buenos Aires

Argentina  
C1417EYG

**Study participating centre**  
**CEDIC Centro de Investigaciones Clinicas**  
Avenida Santa Fe 1480  
Caba  
Argentina  
C1060ABN

**Study participating centre**  
**Conexa Investigacion Clinica S.A.**  
Libertad 1213  
Caba  
Argentina  
C1012AAY

**Study participating centre**  
**CIPREC**  
Arenales 1611 2 Piso  
Ciudad Autonoma de Buenos Aires  
Argentina  
C1061AAS

**Study participating centre**  
**Hospital Central Militar Cirujano Mayor Dr Cosme Argerich**  
Av. Luis Maria Campos 726  
Caba  
Argentina  
C1426BOS

**Study participating centre**  
**Instituto Medico de La Fundacion Estudios Clinicos**  
Italia 428  
Rosario  
Argentina  
2000

**Study participating centre**

**Skinsense Medical Research**

411 2nd Avenue North  
Saskatoon  
Canada  
S7K 2C1

**Study participating centre**

**Innovaderm Research Inc.**

3530 boulevard Saint-Laurent  
Montreal  
Canada  
H2X 2V1

**Study participating centre**

**York Dermatology Clinic and Research Centre**

250 Harding Blvd. West  
Richmond Hill  
Canada  
L4C 9M7

**Study participating centre**

**Skin Centre for Dermatology**

775 Monaghan Rd South  
Peterborough  
Canada  
K9J 5K2

**Study participating centre**

**Lynderm Research Inc.**

25 Main Street Markham North  
Markham  
Canada  
L3P 1X3

**Study participating centre**

**Alberta DermaSurgery Centre**

7609 - 109 Street NW  
Edmonton  
Canada  
T6G 1C3

**Study participating centre**

**Centre De Recherche Dermatologique Du Quebec Metropolitan**

2880 Chemin Quatre-Bouregois

Quebec

Canada

G1V 4X7

**Study participating centre**

**Medizinische Fakultat Carl Gustav Carus Technische Universitat Dresden**

Fetscherstr. 74

Dresden

Germany

01307

**Study participating centre**

**Universitaetsklinikum Frankfurt**

Theodor-Stern-Kai 7

Frankfurt am Main

Germany

60590

**Study participating centre**

**ISA - Interdisciplinary Study Association GmbH**

Rankestrasse 33-34

Berlin

Germany

10789

**Study participating centre**

**Klinische Forschung Schwerin GmbH**

Friedrichstrasse 1

Schwerin

Germany

19055

**Study participating centre**

**Hautarztpraxis**

Annenstraße 151

Witten

Germany  
58453

**Study participating centre**  
**Niesmann & Othlinghaus GbR**  
Alleestraße 80  
Bochum  
Germany  
44793

**Study participating centre**  
**Rosenpark Research GmbH**  
Rheinstrasse 14  
Darmstadt  
Germany  
64283

**Study participating centre**  
**Dermatologikum Hamburg GmbH**  
Stephansplatz 5  
Hamburg  
Germany  
20354

**Study participating centre**  
**CRS Clinical Research Services Berlin GmbH**  
Siemensdamm 65  
Berlin  
Germany  
13627

**Study participating centre**  
**Obudai Egeszsegugyi Centrum Kft.**  
Lajos utca 74  
Budapest  
Hungary  
1036

**Study participating centre**

**Somogy Megyei Kaposi Mor Oktato Korhaz**  
Tallian Gyula utca 20-32  
Kaposvar  
Hungary  
7400

**Study participating centre**  
**SZTE AOK Szent-Gyorgyi Albert Klinikai Kozpont, Borgyogyaszati és Allergologiai Klinika**  
Koranyi fasor 6.  
Szeged  
Hungary  
6720

**Study participating centre**  
**Pecsi Tudomanyegyetem**  
Akac u. 1  
Borgyogyaszati Klinika  
Hungary  
7632

**Study participating centre**  
**Derma-B Kft**  
Gyepusor utca 3. Fsz.  
Debrecen  
Hungary  
4031

**Study participating centre**  
**Medmare Egeszsegugyi Es Szolgaltato Bt.**  
Jozsef Attila u.17,  
Veszprem  
Hungary  
8200

**Study participating centre**  
**Debreceni Egyetem Klinikai Kozpont**  
Nagyerdei korut 98  
Debrecen  
Hungary  
4032

**Study participating centre**

**Allergo-Derm Bakos Kft.**

Baross utca 20.

Szolnok

Hungary

5000

**Study participating centre**

**Seoul National University Hospital**

101 Daehak-ro, Jongno-gu

Seoul

Korea, South

03080

**Study participating centre**

**Seoul National University Bundang Hospital**

82, Gumi-ro 173beon-gil, Bundang-gu, Seongnam-si

Gyeonggi-do

Korea, South

13620

**Study participating centre**

**Pusan National University Hospital**

179 Gudeok-Ro, Seo-Gu

Busan

Korea, South

49241

**Study participating centre**

**Konkuk University Medical Center**

120-1 NeunGdong-ro, Gwangjin-Gu

Seoul

Korea, South

05030

**Study participating centre**

**Korea University Guro Hospital**

148, Gurodong-Ro

Seoul



Korea, South  
152-703

**Study participating centre**

**WroMedica I.Bielicka, A.Strzałkowska s.c.**  
ul. A. Mickiewicza 91  
Wrocław  
Poland  
51-685

**Study participating centre**

**DermaDent Centrum Medyczne Aldona Czajkowska Rafał Czajkowski s.c.**  
Tuberozy 3  
Osielsko  
Poland  
86031

**Study participating centre**

**Osteo-Medic s.c A. Racewicz, J Supronik**  
ul. Wiejska 81  
Białystok  
Poland  
15-351

**Study participating centre**

**Dermed Centrum Medyczne Sp. z o.o**  
ul. Piotrkowska 48  
Lodz  
Poland  
90-265

**Study participating centre**

**Klinika Ambroziak Estederm Sp. z o.o**  
Sikorskiego 13/U1  
Warszawa  
Poland  
02-758

**Study participating centre**

**Lidia Rajzer - Specjalistyczny Gabinet Dermatologiczno-Kosmetyczny**

Borkowska 29A/9

Krakow

Poland

30-438

**Study participating centre**

**Przychodnia Specjalistyczna High-Med**

27 Jana Kasprowicza

Warszawa

Poland

01-817

**Study participating centre**

**Specjalistyczny gabinet dermatologiczny Aplikacyjno-Badawczy Marek Brzewski, Pawel Brzewski**

**Spolka Cywilna**

Zbozowa

Krakow

Poland

30-002

**Study participating centre**

**Centrum Kliniczno Badawcze J. Brzezicki, B. Gornikiewicz-Brzezicka Lekarze Spolka Partnerska**

Studzienne 35-36/A

Elblag

Poland

82-300

**Study participating centre**

**Centrum Medyczne Promed**

ul. Nad Struga 7

Krakow

Poland

31-411

**Study participating centre**

**SOLUMED Centrum Medyczne**

ul. Dąbrowskiego 77a (Budynek Nobel Tower)

Poznan

Poland

60-529

**Study participating centre**  
**Centrum Medyczne Oporow**  
ul. Ludwika Solskiego 4a/1  
Wroclaw  
Poland  
52-416

**Study participating centre**  
**Specderm Poznańska sp. j.**  
ul. Prezydenta Ryszarda Kaczorowskiego 7 lok. 50 U  
Bialystok  
Poland  
15-375

**Study participating centre**  
**DERMMEDICA Sp.z o.o.**  
ul. Zakrzowska 19 a  
Wroclaw  
Poland  
51-318

**Study participating centre**  
**Clinical Research Center sp. z o.o MEDIC-R s.k.**  
ul. Poznanska 3 lok. 31  
Poznan  
Poland  
60-848

**Study participating centre**  
**HOSP. UNIV. 12 DE OCTUBRE**  
Avenida de Cordoba, km 5,4  
Madrid  
Spain  
28041

**Study participating centre**  
**HOSP. UNIV. I POLITECNI LA FE**  
Avda. Fernando Abril Martorell, 106

Valencia  
Spain  
46026

**Study participating centre**

**HOSP. DE MANISES**

Avenida de la Generalitat Valenciana 50  
Manises  
Spain  
46940

**Study participating centre**

**HOSP. UNIV. SAN CECILIO**

Avenida del Conocimiento 33  
Granada  
Spain  
18016

**Study participating centre**

**HOSP. VIRGEN MACARENA**

Avenida Doctor Fedriani, nº 3  
Sevilla  
Spain  
41009

**Study participating centre**

**HOSP. UNIV. GERMANS TRIAS I PUJOL**

Carretera de Canyet s/n  
Badalona  
Spain  
08916

**Study participating centre**

**HOSP. SANT JOAN DE DEU**

Passeig Sant Joan de Déu 2  
Esplugues de Llobregat  
Spain  
08950

**Study participating centre**

**HOSP. DEL MAR**

Passeig Maritim, 25-29

Barcelona

Spain

08003

**Study participating centre**

**National Taiwan University Hospital**

No.1, Changde St., Zhongzheng Dist.

Taipei

Taiwan

10048

**Study participating centre**

**Linkou Chang Gung Memorial Hospital**

No.5 Fuxing street

Taoyuan

Taiwan

33382

**Study participating centre**

**Kaohsiung Chang Gung Memorial Hospital**

No. 123, DAPI Road, Niasng District

Kaohsiung

Taiwan

83301

**Study participating centre**

**National Taiwan University Hospital Hsin-Chu Branch**

Room 57, 1F, No.25, Lane 442, Sec.1, Jingguo Rd.

Hsinchu

Taiwan

300

**Study participating centre**

**Istanbul University Cerrahpasa Medical Faculty**

Kocamustafapasa Cad. Cerrahpasa No: 53

Istanbul

Türkiye

34098

**Study participating centre**  
**Ondokuz Mayıs University**  
Ondokuz Mayıs Unv  
Samsun  
Türkiye  
55270

**Study participating centre**  
**Karadeniz Teknik University Medical Faculty**  
Farabi cad.  
Trabzon  
Türkiye  
61080

**Study participating centre**  
**Necmettin Erbakan University Meram Medical Faculty**  
Meram  
Konya  
Türkiye  
42080

**Study participating centre**  
**Pamukkale University Medical Faculty**  
Camlaraltı, Kinikli Yerleskesi, Universite Cd. No:11  
Denizli  
Türkiye  
20070

**Study participating centre**  
**Ankara Etlik Speciality Hospital**  
Varlık, Halil Sezai Erkut Cd. No:5  
Ankara  
Türkiye  
06170

**Study participating centre**  
**Newcastle upon Tyne Hospitals NHS Foundation Trust**  
New Victoria Wing, Level 2, Queen Victoria Road

Newcastle upon Tyne  
United Kingdom  
NE1 4LP

**Study participating centre**  
**University Hospital Southampton NHS Foundation Trust**  
Southampton General Hospital  
Southampton  
United Kingdom  
SO16 6YD

**Study participating centre**  
**Northwick Park Hospital**  
Watford Road  
London  
United Kingdom  
HA1 3UJ

**Study participating centre**  
**Victoria Hospital**  
Phase 1, Level 2  
Kirkcaldy  
United Kingdom  
KY2 5AH

**Study participating centre**  
**Salford Royal Hospital**  
Stott Lane  
Salford  
United Kingdom  
M6 8HD

**Study participating centre**  
**Northshore Medical Group**  
9933 Woods Dr  
Skokie  
United States of America  
60076

**Study participating centre**  
**Oregon Dermatology and Research Center**  
2565 NW Lovejoy  
Portland  
United States of America  
97210

**Study participating centre**  
**Arlington Research Center, Inc.**  
711 East Lamar Boulevard, Ste 200  
Arlington  
United States of America  
76011

**Study participating centre**  
**Center for Clinical Studies**  
451 North Texas Avenue  
Webster  
United States of America  
77598

**Study participating centre**  
**Progressive Clinical Research**  
1973 N.W. Loop 410  
San Antonio  
United States of America  
78213

**Study participating centre**  
**Skin Specialists**  
2802 Oak View Drive  
Omaha  
United States of America  
68144

**Study participating centre**  
**Dermatology and Advanced Aesthetics**  
3635 Nelson Road  
Lake Charles  
United States of America  
70605



**Study participating centre**  
**Optima Research**  
1039 Boardman-Canfield Road  
Boardman  
United States of America  
44512

**Study participating centre**  
**Center for Clinical Studies**  
1401 Binz Street  
Houston  
United States of America  
77004

**Study participating centre**  
**Austin Institute for Clinical Research**  
1601 E Pflugerville Pkwy  
Pflugerville  
United States of America  
78660

**Study participating centre**  
**Minnesota Clinical Study Center**  
119-14th Street N.W.,  
New Brighton  
United States of America  
55112

**Study participating centre**  
**MediSearch Clinical Trials**  
1427 Village Drive  
Saint Joseph  
United States of America  
64506

**Study participating centre**  
**Frontier Derm Partners CRO, LLC**  
15906 Mill Creek Blvd

Mill Creek  
United States of America  
98012

**Study participating centre**  
**Windsor Dermatology**  
59 One Mile Rd Ext Ste G  
East Windsor  
United States of America  
8520

**Study participating centre**  
**Dermatology Clinical Research Center of San Antonio**  
7810 Louis Pasteur Dr Ste 200  
San Antonio  
United States of America  
78229

**Study participating centre**  
**FORCARE CLINICAL RESEARCH, INC.**  
15416 North Florida Avenue  
Tampa  
United States of America  
33613

**Study participating centre**  
**Dawes Fretzin Clinical Research Group, LLC**  
7910 North Shadeland Avenue  
Indianapolis  
United States of America  
46250

**Study participating centre**  
**Dundee Dermatology**  
1201 Water Tower Rd  
West Dundee  
United States of America  
60118

**Study participating centre**  
**Indiana Clinical Trial Center**  
824 Edwards Drive  
Plainfield  
United States of America  
46168

**Study participating centre**  
**Johnson Dermatology**  
5921 Riley Park Drive  
Fort Smith  
United States of America  
72916

**Study participating centre**  
**Hamilton Research, LLC.**  
11800 Atlantis Place  
Alpharetta  
United States of America  
30022

**Study participating centre**  
**University of Pittsburgh Medical Center**  
3601 5Th Ave  
Pittsburgh  
United States of America  
15213

**Study participating centre**  
**Arlington Dermatology**  
5301 Keystone Ct.  
Rolling Meadows  
United States of America  
60008

**Study participating centre**  
**Hamzavi Dermatology**  
2950 Keewahdin Road  
Fort Gratiot  
United States of America  
48059

**Study participating centre**

**Allcutis Research**

138 Conant Street  
Beverly  
United States of America  
01915

**Study participating centre**

**California Dermatology & Clinical Research Institute**

561 Saxony Place  
Encinitas  
United States of America  
92024

**Study participating centre**

**Center for Dermatology and Plastic Surgery**

14301 N 87th St  
Scottsdale  
United States of America  
85260

**Study participating centre**

**Cope Family Medicine - Ogden Clinic**

185 S 400 E  
Bountiful  
United States of America  
84010

**Study participating centre**

**DermAssociates, PC**

15245 Shady Grove Road  
Rockville  
United States of America  
20850

**Study participating centre**

**Paddington Testing Co, Inc.**

1845 Walnut Street

Philadelphia  
United States of America  
19103

## Sponsor information

### Organisation

Janssen-Cilag International NV

### Sponsor details

Clinical Registry Group, Archimedesweg 29  
Leiden  
Netherlands  
2333 CM

-  
ClinicalTrialsEU@its.jnj.com

### Sponsor type

Industry

### Website

<https://www.janssen.com/netherlands/>

## Funder(s)

### Funder type

Industry

### Funder Name

Janssen Research and Development

### Alternative Name(s)

Janssen R&D, Janssen Research & Development, Janssen Research & Development, LLC, Janssen Research & Development LLC, Janssen Pharmaceutical Companies of Johnson & Johnson, Research & Development at Janssen, JRD, J&J PRD

### Funding Body Type

Private sector organisation

### Funding Body Subtype

For-profit companies (industry)

### Location

United States of America

# Results and Publications

## Publication and dissemination plan

1. Peer-reviewed scientific journals
2. Internal report
3. Conference presentation
4. Submission to regulatory authorities
5. Study results will be available to participants via the provision of a Plain Language Summary at the end of the study and in addition results will be published in the EudraCT database

## Intention to publish date

10/07/2030

## Individual participant data (IPD) sharing plan

The data sharing policy of the Janssen Pharmaceutical Companies of Johnson & Johnson is available at <https://www.janssen.com/clinicaltrials/transparency>. As noted on this site, requests for access to the study data can be submitted through the Yale Open Data Access (YODA) Project site at [yoda.yale.edu](http://yoda.yale.edu)

## IPD sharing plan summary

Available on request